Get the Stockscreener App
0.325
2.54%
0.008
Plus Therapeutics Inc stock is traded at $0.325, with a volume of 2.55M.
It is up +2.54% in the last 24 hours and up +5.23% over the past month.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
See More
Previous Close:
$0.317
Open:
$0.3165
24h Volume:
2.55M
Relative Volume:
0.10
Market Cap:
$16.58M
Revenue:
-
Net Income/Loss:
$-12.89M
P/E Ratio:
-0.1285
EPS:
-2.53
Net Cash Flow:
$-11.95M
1W Performance:
-7.87%
1M Performance:
+5.23%
6M Performance:
-72.69%
1Y Performance:
-82.80%
1-Day Range:
$0.3165
$0.339
1-Week Range:
$0.3165
$0.365
52-Week Range:
$0.1634
$2.3099
Plus Therapeutics Inc Stock (PSTV) Company Profile
Name
Plus Therapeutics Inc
Sector
Industry
Phone
737.255.7194
Address
4200 MARATHON BLVD., AUSTIN, TX
Compare PSTV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
0.3251 | 16.99M | 0 | -12.89M | -11.95M | -2.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.06 | 119.76B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
553.77 | 59.14B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
315.60 | 41.40B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
570.47 | 32.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
277.65 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-25 | Initiated | D. Boral Capital | Buy |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
| Oct-16-20 | Initiated | Maxim Group | Buy |
Plus Therapeutics Inc Stock (PSTV) Latest News
Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases | PSTV Stock News - GuruFocus
Plus Therapeutics Announces Clinical Trial Presentation and Educational Symposium at 2025 SNO/ASCO CNS Metastases Conference - Nasdaq
Plus Therapeutics Presents ReSPECT-LM Clinical Trial - GlobeNewswire
Breakthrough Phase 1 Trial: REYOBIQ Treatment Shows Encouraging Results for Rare Brain Cancer Metastases - Stock Titan
Plus Therapeutics Announces Two CNSide Presentations at the Upco - GuruFocus
Plus Therapeutics' CNSide Showcases Innovative CSF Assay Data at SNO/ASCO CNS Metastases Conference 2025 - Nasdaq
Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference - GlobeNewswire
Revolutionary CNS Cancer Detection: Plus Therapeutics Unveils Game-Changing Clinical Data at Major Conference - Stock Titan
Plus Therapeutics Soars 10.51% on Promising Clinical Trial Results - AInvest
Plus Therapeutics begins treatment in REYOBIQ dose optimization trial By Investing.com - Investing.com South Africa
Plus Therapeutics Announces Initial Patients Successfully - GlobeNewswire
Plus Therapeutics begins treatment in REYOBIQ dose optimization trial - Investing.com
Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases | PSTV Stock News - GuruFocus
Plus Therapeutics announces initial patients successfully treated in ReSPECT-LM dose optimization trial for Reyobiq™ in leptomeningeal metastases - MarketScreener
Plus Therapeutics Initiates ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases Treatment - Nasdaq
Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases - The Manila Times
Breakthrough Brain Cancer Drug REYOBIQ Achieves 80% Tumor Reduction in Phase 1 Trial, Advances to Next Stage - Stock Titan
Stock under $1with a very strong catalyst to buy and hold for a minimum of three years - AInvest
Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases - The Manila Times
Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM - GuruFocus
Plus Therapeutics stock price target lowered to $3 at H.C. Wainwright - Investing.com India
Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary | PSTV Stock News - GuruFocus
Plus Therapeutics (PSTV) Shares Surge After FDA Trial Clearance - GuruFocus
Plus Therapeutics Soars 122.46% on FDA Clearance for Pediatric Brain Cancer Trial - AInvest
Plus Therapeutics (PSTV) Restructures $15M Equity Financing to Minimize Dilution | PSTV Stock News - GuruFocus
Plus Therapeutics drops 5%, files prospectus for 17M share secondary offering - MSN
Plus (PSTV) Upgraded to Buy: Here's Why - Yahoo Finance
Dow Surges 150 Points; Korn Ferry Earnings Top Views - Benzinga
Plus Therapeutics (PSTV) Sees Stock Dip Amid New Share Sale Fili - GuruFocus
Plus Therapeutics drops 5%, files prospectus for 17M share secondary offering (PSTV:NASDAQ) - Seeking Alpha
Plus Therapeutics (PSTV) Announces Sale of 17 Million Shares | P - GuruFocus
Crude Oil Moves Higher; US Weekly Jobless Claims Decline - Benzinga
Plus Therapeutics Modifies Security Holders’ Rights - TipRanks
Leptomeningeal Metastases Pipeline 2025: MOA, ROA, - openPR.com
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials - AlphaStreet
Plus Therapeutics Appeals Nasdaq Delisting Decision - TipRanks
Plus Therapeutics (NASDAQ:PSTV) Given New $20.50 Price Target at Ascendiant Capital Markets - Defense World
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds - mx.advfn.com
Ascendiant Capital raises Plus Therapeutics stock price target By Investing.com - Investing.com South Africa
Ascendiant Capital raises Plus Therapeutics stock price target - Investing.com
PSTV: Ascendiant Capital Maintains Buy Rating and Raises Price T - GuruFocus
PSTV: Ascendiant Capital Maintains Buy Rating and Raises Price Target | PSTV Stock News - GuruFocus
Plus Therapeutics (NASDAQ:PSTV) Shares Down 6.9% – Here’s What Happened - Defense World
Plus Therapeutics Reports Q1 2025 Financial Results - TipRanks
Plus Therapeutics Plunges 14.13% on Q1 Earnings Miss - AInvest
Why Did Plus Therapeutics (PSTV) Soar 36.24% Pre-Market After Earnings Miss? - AInvest
Plus Therapeutics (PSTV) Reports Significant Q1 Earnings Miss - GuruFocus
Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates - MSN
Plus: Q1 Earnings Snapshot - New Haven Register
Plus Therapeutics reports Q1 EPS ($1.19) vs. (75c) last year - TipRanks
Plus Therapeutics (PSTV) Reports Financial Gains from Grant Reve - GuruFocus
Plus Therapeutics Inc Stock (PSTV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Plus Therapeutics Inc Stock (PSTV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hawkins Richard J | Director |
Sep 13 '24 |
Buy |
1.50 |
4,000 |
5,996 |
15,188 |
| Hawkins Richard J | Director |
Sep 12 '24 |
Buy |
1.35 |
6,285 |
8,512 |
11,188 |
| Petersen Greg | Director |
Sep 11 '24 |
Buy |
1.35 |
12,500 |
16,875 |
48,921 |
| Clowes Howard | Director |
Sep 11 '24 |
Buy |
1.34 |
5,000 |
6,681 |
26,497 |
| HEDRICK MARC H | Chief Executive Officer |
Sep 10 '24 |
Buy |
1.23 |
8,000 |
9,839 |
20,425 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Sep 10 '24 |
Buy |
1.27 |
4,098 |
5,204 |
9,815 |
2.84%
1.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):